Compagnie Lombard Odier SCmA Sells 8,018 Shares of Moderna, Inc. (NASDAQ:MRNA)

Compagnie Lombard Odier SCmA trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 6.2% in the fourth quarter, HoldingsChannel reports. The fund owned 120,286 shares of the company’s stock after selling 8,018 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Moderna were worth $5,001,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Vontobel Holding Ltd. lifted its holdings in shares of Moderna by 122.6% in the 4th quarter. Vontobel Holding Ltd. now owns 258,368 shares of the company’s stock worth $10,743,000 after acquiring an additional 142,280 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of Moderna by 1.1% in the 4th quarter. Asset Management One Co. Ltd. now owns 123,051 shares of the company’s stock worth $4,938,000 after acquiring an additional 1,381 shares during the last quarter. Summit Trail Advisors LLC raised its holdings in Moderna by 36.0% during the 4th quarter. Summit Trail Advisors LLC now owns 7,281 shares of the company’s stock valued at $303,000 after buying an additional 1,927 shares during the last quarter. Empowered Funds LLC raised its holdings in Moderna by 11.2% during the 4th quarter. Empowered Funds LLC now owns 5,781 shares of the company’s stock valued at $240,000 after buying an additional 582 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by insiders.

Moderna Stock Up 4.6 %

Shares of MRNA stock opened at $31.92 on Friday. Moderna, Inc. has a one year low of $30.24 and a one year high of $170.47. The company’s 50-day moving average is $39.31 and its 200 day moving average is $55.94. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MRNA shares. Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Sanford C. Bernstein started coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $66.89.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.